Nanoparticles disguised as red blood cells to evade the immune system

Expert Opinion on Biological Therapy

Volumn 12, Issue 4, 2012, Pages 385-389

  Fang, Ronnie Hongbo ^a   Hu, Che Ming Jack ^a   Zhang, Liangfang ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Biomimetic nanoparticle; Drug delivery; Long circulation; Red blood cell membrane

Indexed keywords

CD47 ANTIGEN; CD59 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; DAUNORUBICIN; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; NANOCARRIER; PHOSPHATE BUFFERED SALINE; POLYGLACTIN; POLYSTYRENE; QUANTUM DOT;

BIOMIMETICS; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; GOLD STANDARD; HALF LIFE TIME; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; PROCESS OPTIMIZATION; REVIEW; SURFACE PROPERTY; SYSTEMIC CIRCULATION;

BIOMIMETIC MATERIALS; DRUG DELIVERY SYSTEMS; ERYTHROCYTES; HUMANS; IMMUNE SYSTEM; NANOPARTICLES;

EID: 84863369402     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.661710     Document Type: Review

References (15)

1. Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006;58:1456-9 (Pubitemid 44820502)
2. Zhang L, Gu FX, Chan JM, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharm Ther 2008;83:761-9 (Pubitemid 351556021)
3. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451-8 (Pubitemid 41483874)
4. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214-21 (Pubitemid 37361666)
5. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed 2010;49:6288-308
6. Muzykantov VR. Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin Drug Deliv 2010;7:403-27
7. Doshi N, Zahr AS, Bhaskar S, et al. Red blood cell-mimicking synthetic biomaterial particles. Proc Natl Acad Sci USA 2009;106:21495-9
8. Merkel TJ, Jones SW, Herlihy KP, et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc Natl Acad Sci USA 2011;108:586-91
9. Oldenborg PA, Zheleznyak A, Fang YF, et al. Role of CD47 as a marker of self on red blood cells. Science 2000;288:2051-4 (Pubitemid 30397687)
10. Schonermark S, Rauterberg EW, Shin ML, et al. Homologous species restriction in lysis of human-erythrocytes - a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immun 1986;136: 1772-6 (Pubitemid 16119589)
11. Zalman LS, Wood LM, Mullereberhard HJ. Isolation of human-erythrocyte membrane-protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci USA 1986;83:6975-9 (Pubitemid 16002352)
12. Kim DD, Miwa T, Kimura Y, et al. Deficiency of decay-accelerating factor and complement receptor 1-related gene/ protein y on murine platelets leads to complement-dependent clearance by the macrophage aphagocytic receptor CRIg. Blood 2008;112:1109-19
13. Tsai RK, Rodriguez PL, Discher DE. Self inhibition of phagocytosis: the affinity of 'marker of self' CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels. Blood Cells Mol Dis 2010;45:67-74
14. Desilets J, Lejeune A, Mercer J, Gicquaud C. Nanoerythrosomes, a new derivative of erythrocyte ghost: IV. Fate of reinjected nanoerythrosomes. Anticancer Res 2001;21:1741-7 (Pubitemid 32728907)
15. Hu CMJ, Zhang L, Aryal S, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as biomimetic delivery platform. Proc Natl Acad Sci USA 2011;108:10980-5